Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company"), one of the world's fastest growing digital healthcare companies, announces that David Humphreys will be appointed as the Company's new Chief Financial Officer. Mr. Humphreys has been at Babylon for nearly two years in the role of Finance Director, with overall responsibility for building and scaling Babylon's finance function. Formerly, he was US-based as a Silicon Valley and New York Partner with PwC for over 20 years, working with Boards and leaders of fast-moving, rapid-growth companies including Tesla and Facebook to which he provided accounting consulting, transaction, IPO, M&A and auditing services to ensure complianc

Babylon Holdings Limited (the "Company" or "Babylon") (NYSE:BBLN) previously announced in its June 23, 2023 press release that the Company has received a proposal from AlbaCore Capital LLP ("AlbaCore") and MindMaze Group SA ("MindMaze") pursuant to which core operating subsidiaries of the Company would be transferred to MindMaze (the "Proposed Transaction"). The closing of the Proposed Transaction is expected in July 2023 and is subject to agreed documentation, various conditions and appropriate approvals, if required. The Proposed Transaction will not provide for any payment to the Company's Class A ordinary shareholders or other equity instrument holders, as AlbaCore will be exercising ri

After a thorough exploration of strategic alternatives, Babylon Holdings Limited (NYSE:BBLN) (including its subsidiaries, "Babylon") is pleased to provide an update on the recapitalization transaction, previously announced on May 10, following receipt of a proposal from AlbaCore Capital LLP on behalf of certain of its affiliates ("AlbaCore") and MindMaze Group SA ("MindMaze"), and share that Babylon has selected the previously announced take private proposal from the options considered. The proposal strongly positions Babylon to accelerate its core mission – to make high quality healthcare more accessible and affordable by combining the most cutting-edge technology with the best medical ex

Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company") today announced its financial and operating results for the first quarter ended March 31, 2023. First Quarter Financial Results Comparison of the following financial results for the three months ended March 31, 2023, to the three months ended March 31, 2022: Total revenue was $311.1 million compared to $266.4 million, a 1.2x year-over-year increase of $44.7 million. This was primarily due to the growth in VBC revenue, which increased by 17% year-over-year to $287.5 million in Q1 2023. Net loss totaled $63.2 million, a (20.3)% Net loss margin compared to Net loss of $29.1 million, a (10.9)% Net loss margin in Q1 2022

Babylon Holdings Limited (NYSE:BBLN) (including its subsidiaries, "Babylon") is pleased to announce that it has entered into an amendment and restatement of its senior secured term loan facility with AlbaCore Capital LLP and certain of its affiliates ("AlbaCore"), dated March 9, 2023 (the "Bridge Facility Agreement"), for up to an additional $34.5 million in funding (the "Interim Funding"). This investment demonstrates AlbaCore's ongoing support to Babylon. The Interim Funding will be provided on similar pricing terms to the original Bridge Facility Agreement. The Interim Funding will provide liquidity to support Babylon's operations and enable Babylon to proceed with a proposed longer-te

Babylon (NYSE:BBLN) (the "Company") today announced it will host a conference call to review its first quarter financial results on Wednesday, May 10, 2023, at 8:00 AM Eastern Time. A press release announcing the results will be issued prior to the conference call on Wednesday, May 10, 2023. To participate in the live conference call and webcast, please dial (877) 407-7994 for U.S. participants, 0 800 756 3429 for U.K. participants or +1 215-268-9868 for international participants. Alternatively, you can visit the "News & Events" section of https://ir.babylonhealth.com to access the live webcast. On this page, you can also find a "Call me" link for instant telephone access to the event, w

Chronic conditions include diabetes, hypertension, anxiety, depression, low back pain, and prenatal care Babylon's technology will collect and analyze data to monitor patients in real-time Personalized care teams will tailor evidence-based programs for each member Care is integrated into Babylon's single platform for a seamless experience for both providers and members Babylon (NYSE:BBLN), a global digital healthcare company, announced today personalized, digital-first programs for high-risk members living with chronic conditions. The care pathways were developed hand-in-hand by Babylon's expert technologists and primary care teams for a true end-to-end value-based care system. The

Revenue grew 3.5x YoY, to $1.11 billion, exceeding guidance Cost of Care Delivery (COCD) Margin in the U.K. already profitable1, with U.S. Clinical services also expecting COCD profitability in early 2023 Key U.S. VBC contracts delivered profitable Medical Margins2 in their first year Monthly Adjusted EBITDA of $(16.3) million for Q4 2022 beating guidance of $(18) million Adjusted EBITDA profitability expected in mid-2024, significantly earlier than previous guidance Commercial VBC revenue substantially increased with recent launch of Ambetter digital-first service across 6 states Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company") today announced its financial an

Babylon (NYSE:BBLN) (the "Company") today announced it will host a conference call to review its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, at 8:00 AM Eastern Time. A press release announcing the results will be issued prior to the conference call on Thursday, March 9, 2023. To participate in the live conference call and webcast, please dial (877) 407-7994 for U.S. participants, 0 800 756 3429 for U.K. participants or +1 215-268-9868 for international participants. Alternatively, you can visit the "News & Events" section of https://ir.babylonhealth.com to access the live webcast. On this page, you can also find a "Call me" link for instant telephone acc

Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company") today confirmed that its revenue for the year ended December 31, 2022 is expected to exceed $1.05 billion on both a U.S. GAAP and International Financial Reporting Standards (IFRS) basis, including revenue from the IPA business in California. Babylon also expects to beat its previous IFRS Adjusted EBITDA guidance of $(270) million or less for 2022. These financial results are preliminary, unaudited and subject to change in connection with the completion of Babylon's financial closing process and the preparation of its audited financial statements for 2022. In July 2022, Babylon announced cost reductions expected to deliver u

Babylon (NYSE:BBLN) ("Babylon'') today announced additional details concerning the previously announced 1-for-25 reverse share split (the "Reverse Share Split") of its Class A ordinary shares, par value $0.0000422573245084686 per share (the "Class A Ordinary Shares"), which will become effective on December 15, 2022 (the "Effective Date"). These shares are expected to begin trading on a split-adjusted basis at market open on December 16, 2022. The Reverse Share Split is intended to increase the per share trading price of the Class A Ordinary Shares to enable Babylon to regain compliance with the New York Stock Exchange minimum share price requirement. Babylon believes that the Reverse Shar

4 - Babylon Holdings Ltd (0001866390) (Issuer)

4 - Babylon Holdings Ltd (0001866390) (Issuer)

4 - Babylon Holdings Ltd (0001866390) (Issuer)

4 - Babylon Holdings Ltd (0001866390) (Issuer)

4 - Babylon Holdings Ltd (0001866390) (Issuer)

4 - Babylon Holdings Ltd (0001866390) (Issuer)

4 - Babylon Holdings Ltd (0001866390) (Issuer)

4 - Babylon Holdings Ltd (0001866390) (Issuer)

3 - Babylon Holdings Ltd (0001866390) (Issuer)

4 - Babylon Holdings Ltd (0001866390) (Issuer)

Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company") today announced its financial and operating results for the first quarter ended March 31, 2023. First Quarter Financial Results Comparison of the following financial results for the three months ended March 31, 2023, to the three months ended March 31, 2022: Total revenue was $311.1 million compared to $266.4 million, a 1.2x year-over-year increase of $44.7 million. This was primarily due to the growth in VBC revenue, which increased by 17% year-over-year to $287.5 million in Q1 2023. Net loss totaled $63.2 million, a (20.3)% Net loss margin compared to Net loss of $29.1 million, a (10.9)% Net loss margin in Q1 2022

Babylon (NYSE:BBLN) (the "Company") today announced it will host a conference call to review its first quarter financial results on Wednesday, May 10, 2023, at 8:00 AM Eastern Time. A press release announcing the results will be issued prior to the conference call on Wednesday, May 10, 2023. To participate in the live conference call and webcast, please dial (877) 407-7994 for U.S. participants, 0 800 756 3429 for U.K. participants or +1 215-268-9868 for international participants. Alternatively, you can visit the "News & Events" section of https://ir.babylonhealth.com to access the live webcast. On this page, you can also find a "Call me" link for instant telephone access to the event, w

Revenue grew 3.5x YoY, to $1.11 billion, exceeding guidance Cost of Care Delivery (COCD) Margin in the U.K. already profitable1, with U.S. Clinical services also expecting COCD profitability in early 2023 Key U.S. VBC contracts delivered profitable Medical Margins2 in their first year Monthly Adjusted EBITDA of $(16.3) million for Q4 2022 beating guidance of $(18) million Adjusted EBITDA profitability expected in mid-2024, significantly earlier than previous guidance Commercial VBC revenue substantially increased with recent launch of Ambetter digital-first service across 6 states Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or the "Company") today announced its financial an

Babylon (NYSE:BBLN) (the "Company") today announced it will host a conference call to review its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, at 8:00 AM Eastern Time. A press release announcing the results will be issued prior to the conference call on Thursday, March 9, 2023. To participate in the live conference call and webcast, please dial (877) 407-7994 for U.S. participants, 0 800 756 3429 for U.K. participants or +1 215-268-9868 for international participants. Alternatively, you can visit the "News & Events" section of https://ir.babylonhealth.com to access the live webcast. On this page, you can also find a "Call me" link for instant telephone acc

Third quarter revenue grew 3.9x year-over-year to $288.9 million U.S. value-based care members grew by 171% year-over-year, including 285% growth in Medicare membership Adjusted EBITDA Margin of (18.8)% for the quarter (equivalent to $(18.1) million Adjusted EBITDA per month), a 45 percentage points improvement year-over-year, reflecting successful execution of cost reduction actions Partnering with Ambetter Health to provide digital-first value-based care services to Commercial Exchange members across 6 U.S. states from January 2023, as well as extending key partnership with Bupa in the UK to cover 2.3 million customers Members enrolled in integrated behavioral health programs exp

Babylon (NYSE:BBLN) ("Babylon" or the "Company") today announced it will host a conference call to review the Company's third quarter 2022 financial results in full on Thursday, November 10, 2022, at 8:00 AM Eastern Time. A press release announcing the third quarter results will be issued prior to the conference call on Thursday, November 10, 2022. To participate in the live conference call and webcast, please dial (877) 407-7994 for U.S. participants, 0 800 756 3429 for U.K. participants, or +1 215-268-9868 for international participants. Alternatively, you can visit the "News & Events" section of https://ir.babylonhealth.com to access the live webcast. On this page, you can also find a "

Second quarter revenue grew 4.6x year-over-year to $265.4 million U.S. value-based care members grew by 220% year-over-year Adjusted EBITDA Margin of (25.9)% for the quarter, a 60% improvement year-over-year Reiterating full year 2022 revenue guidance of $1.0 billion or greater and reiterating improved Adjusted EBITDA guidance of $(270.0) million Babylon Holdings Limited (NYSE:BBLN) ("Babylon"), one of the world's fastest-growing digital healthcare companies, today announced its financial and operating results for the second quarter ended June 30, 2022. "Babylon has once again delivered very strong results that demonstrate our continued momentum," said Ali Parsa, CEO and Founder o

Babylon (NYSE:BBLN) ("Babylon" or the "Company") today announced it will host a conference call to review the Company's second quarter 2022 financial results in full on Tuesday, August 9, 2022, at 5:00 PM Eastern Time. A press release announcing the second quarter results will be issued prior to the conference call on Tuesday, August 9, 2022. To participate in the live conference call and webcast, please dial (866) 682-6100 for U.S. participants, 0800 756 3429 for U.K. participants, or +1 862-298-0702 for international participants. Alternatively, you can visit the "News & Events" section of https://ir.babylonhealth.com to access the live webcast. On this page, you can also find a "Call me

First quarter 2022 revenue grew over 3.5x year-over-year to $266 million Increasing 2022 guidance for revenue to $1.0 billion or greater and updating Adjusted EBITDA guidance Adjusted EBITDA Margin of (27)% for the quarter, ahead of previous full-year 2022 guidance of (30)% U.S. value-based care members grew by 63% from Q4 2021 to a total of more than 270,000 members Babylon Holdings Limited (NYSE:BBLN) ("Babylon" or "the Company"), one of the world's fastest growing digital healthcare companies, today announced its financial and operating results for the first quarter ended March 31, 2022. "Babylon has started 2022 with as much momentum as we finished 2021," said Ali Parsa, CEO a

Babylon (NYSE:BBLN) ("Babylon" or the "Company") will host a conference call on Thursday, May 12, 2022, at 8:00 AM Eastern Time to review the Company's first quarter 2022 financial results. A press release announcing the first quarter results will be issued prior to the conference call on Thursday, May 12, 2022. To participate in the Company's live conference call and webcast, please dial 877-407-7994 for U.S. participants, 0 800 756 3429 for U.K. participants, or +1 215-268-9868 for international participants. Alternatively, you can visit the "News & Events" section of https://ir.babylonhealth.com to access the live webcast. On this page, you can also find a "Call me" link for instant tel

BTIG Research downgraded Babylon from Buy to Neutral

BTIG Research reiterated coverage of Babylon with a rating of Buy and set a new price target of $20.00 from $4.00 previously

BofA Securities initiated coverage of Babylon with a rating of Neutral and set a new price target of $2.00

Berenberg initiated coverage of Babylon with a rating of Hold and set a new price target of $5.50

Deutsche Bank initiated coverage of Babylon Holdings with a rating of Buy and set a new price target of $9.00

Citigroup initiated coverage of Babylon with a rating of Neutral and set a new price target of $8.00

Canaccord Genuity initiated coverage of Babylon Holdings with a rating of Buy and set a new price target of $14.00

Jefferies initiated coverage of Babylon Holdings with a rating of Hold and set a new price target of $9.00

BTIG Research initiated coverage of Babylon with a rating of Buy and set a new price target of $15.00